Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases
Metabolic syndrome is estimated to affect more than one in five adults, and its prevalence is growing in the adult and pediatric populations. The most widely recognized metabolic risk factors are atherogenic dyslipidemia, elevated blood pressure, and elevated plasma glucose. Individuals with these c...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2013-01-01
|
| Series: | Mediators of Inflammation |
| Online Access: | http://dx.doi.org/10.1155/2013/549627 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832564905853583360 |
|---|---|
| author | Francisco A. Monsalve Radha D. Pyarasani Fernando Delgado-Lopez Rodrigo Moore-Carrasco |
| author_facet | Francisco A. Monsalve Radha D. Pyarasani Fernando Delgado-Lopez Rodrigo Moore-Carrasco |
| author_sort | Francisco A. Monsalve |
| collection | DOAJ |
| description | Metabolic syndrome is estimated to affect more than one in five adults, and its prevalence is growing in the adult and pediatric populations. The most widely recognized metabolic risk factors are atherogenic dyslipidemia, elevated blood pressure, and elevated plasma glucose. Individuals with these characteristics commonly manifest a prothrombotic state and a proinflammatory state as well. Peroxisome proliferator-activated receptors (PPARs) may serve as potential therapeutic targets for treating the metabolic syndrome and its related risk factors. The PPARs are transcriptional factors belonging to the ligand-activated nuclear receptor superfamily. So far, three isoforms of PPARs have been identified, namely, PPAR-α, PPAR-β/δ, and PPAR-γ. Various endogenous and exogenous ligands of PPARs have been identified. PPAR-α and PPAR-γ are mainly involved in regulating lipid metabolism, insulin sensitivity, and glucose homeostasis, and their agonists are used in the treatment of hyperlipidemia and T2DM. Whereas PPAR-β/δ function is to regulate lipid metabolism, glucose homeostasis, anti-inflammation, and fatty acid oxidation and its agonists are used in the treatment of metabolic syndrome and cardiovascular diseases. This review mainly focuses on the biological role of PPARs in gene regulation and metabolic diseases, with particular focus on the therapeutic potential of PPAR modulators in the treatment of thrombosis. |
| format | Article |
| id | doaj-art-a7577162599546da9ab5dad8233a0c03 |
| institution | Kabale University |
| issn | 0962-9351 1466-1861 |
| language | English |
| publishDate | 2013-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Mediators of Inflammation |
| spelling | doaj-art-a7577162599546da9ab5dad8233a0c032025-02-03T01:10:00ZengWileyMediators of Inflammation0962-93511466-18612013-01-01201310.1155/2013/549627549627Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic DiseasesFrancisco A. Monsalve0Radha D. Pyarasani1Fernando Delgado-Lopez2Rodrigo Moore-Carrasco3Departamento Ciencias Biomédicas, Facultad Ciencias de la Salud, Universidad de Talca, ChileInstituto de Químicas y Recursos Naturales, Universidad de Talca, ChileFacultad de Medicina, Universidad Católica del Maule, ChileDepartamento de Bioquímica Clínica e Inmunohematología, Facultad Ciencias de la Salud, Universidad de Talca, ChileMetabolic syndrome is estimated to affect more than one in five adults, and its prevalence is growing in the adult and pediatric populations. The most widely recognized metabolic risk factors are atherogenic dyslipidemia, elevated blood pressure, and elevated plasma glucose. Individuals with these characteristics commonly manifest a prothrombotic state and a proinflammatory state as well. Peroxisome proliferator-activated receptors (PPARs) may serve as potential therapeutic targets for treating the metabolic syndrome and its related risk factors. The PPARs are transcriptional factors belonging to the ligand-activated nuclear receptor superfamily. So far, three isoforms of PPARs have been identified, namely, PPAR-α, PPAR-β/δ, and PPAR-γ. Various endogenous and exogenous ligands of PPARs have been identified. PPAR-α and PPAR-γ are mainly involved in regulating lipid metabolism, insulin sensitivity, and glucose homeostasis, and their agonists are used in the treatment of hyperlipidemia and T2DM. Whereas PPAR-β/δ function is to regulate lipid metabolism, glucose homeostasis, anti-inflammation, and fatty acid oxidation and its agonists are used in the treatment of metabolic syndrome and cardiovascular diseases. This review mainly focuses on the biological role of PPARs in gene regulation and metabolic diseases, with particular focus on the therapeutic potential of PPAR modulators in the treatment of thrombosis.http://dx.doi.org/10.1155/2013/549627 |
| spellingShingle | Francisco A. Monsalve Radha D. Pyarasani Fernando Delgado-Lopez Rodrigo Moore-Carrasco Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases Mediators of Inflammation |
| title | Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases |
| title_full | Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases |
| title_fullStr | Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases |
| title_full_unstemmed | Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases |
| title_short | Peroxisome Proliferator-Activated Receptor Targets for the Treatment of Metabolic Diseases |
| title_sort | peroxisome proliferator activated receptor targets for the treatment of metabolic diseases |
| url | http://dx.doi.org/10.1155/2013/549627 |
| work_keys_str_mv | AT franciscoamonsalve peroxisomeproliferatoractivatedreceptortargetsforthetreatmentofmetabolicdiseases AT radhadpyarasani peroxisomeproliferatoractivatedreceptortargetsforthetreatmentofmetabolicdiseases AT fernandodelgadolopez peroxisomeproliferatoractivatedreceptortargetsforthetreatmentofmetabolicdiseases AT rodrigomoorecarrasco peroxisomeproliferatoractivatedreceptortargetsforthetreatmentofmetabolicdiseases |